{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008844","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.409463+00:00","generated_at":"2026-06-01T06:43:43.195728+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML","bullets":["Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.","Cohort 2 (relapsed/refractory AML): 55% of evaluable patients (12/23) achieved CR/CRi/CRh; median age 63 yrs.","Safety profile consistent with decitabine+venetoclax; common AEs: fatigue (72%), anemia (60%), neutropenia (49%).","Bio-Path plans to continue enrollment up to 98 evaluable in Cohort 1 and 54 evaluable in Cohort 2.","Data presented as oral presentation at ASCO 2024 by MD Anderson investigator; CEO highlights unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008844","json":"https://secwatch.observer/filing/0001558370-24-008844.json","markdown":"https://secwatch.observer/filing/0001558370-24-008844.md","text":"https://secwatch.observer/filing/0001558370-24-008844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/0001558370-24-008844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/bpth-20240603x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:43:43.195728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}